NORD Stock Overview
A biotechnology company, engages in the cancer diagnostic activities.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Norda ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 41.50 |
| 52 Week High | NOK 0 |
| 52 Week Low | NOK 0 |
| Beta | 0 |
| 11 Month Change | 0.24% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | 38.33% |
| Change since IPO | -99.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| NORD | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | 0.2% | -0.9% | -0.2% |
| 1Y | n/a | -69.8% | -0.5% |
Return vs Industry: Insufficient data to determine how NORD performed against the Norwegian Biotechs industry.
Return vs Market: Insufficient data to determine how NORD performed against the Norwegian Market.
Price Volatility
| NORD volatility | |
|---|---|
| NORD Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in NO Market | 10.8% |
| 10% least volatile stocks in NO Market | 2.7% |
Stable Share Price: NORD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NORD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1 | Frode Westvold | www.nordasa.no |
Norda ASA, a biotechnology company, engages in the cancer diagnostic activities. The company is involved in the research and development of Genefec, a diagnostic screening test for colorectal cancer. It also invests and trades in securities, real estates, and other assets.
Norda ASA Fundamentals Summary
| NORD fundamental statistics | |
|---|---|
| Market cap | NOK 206.29m |
| Earnings (TTM) | NOK 100.24m |
| Revenue (TTM) | NOK 127.97m |
0.0x
P/E Ratio0.0x
P/S RatioIs NORD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NORD income statement (TTM) | |
|---|---|
| Revenue | NOK 127.97m |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 127.97m |
| Other Expenses | NOK 27.73m |
| Earnings | NOK 100.24m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NORD perform over the long term?
See historical performance and comparison